Weaning time (from randomization to extubation) based on ICU type: medical‐surgical or surgical only · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
Time to successful extubation · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
Time to first successful spontaneous breathing trial · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
Duration of mechanical ventilation · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
Intensive care unit length of stay (based on type of control arm): predominantly protocolized control strategy · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
Intensive care unit length of stay (based on type of control arm): predominantly non‐protocolized control strategy · patients with weaning time in invasively ventilated critically ill adults
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations: rate of PDEs per participant year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in pulmonary exacerbations: rate of PDEs per participant year compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Quality of life: respiratory domain · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Cerebral palsy ‐ not reported · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Significant mental developmental delay ‐ not reported · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Legal blindness ‐ not reported · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing deficit ‐ not measured · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental impairment (composite outcome) ‐ not measured · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during initial hospitalization ‐ not reported · infants at risk of hypoglycaemia or hyperglycaemia
It is very uncertain whether summary of findings table ‐ Continuous glucose monitoring (CGM) changes death during initial hospitalization (all‐cause mortality) compared with intermittent modalities (very low certainty).
1 finding from 1 review
Neonatal seizures ‐ not reported · infants at risk of hypoglycaemia or hyperglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found